PLACE OF SLT IN THE MANAGEMENT OF GLAUCOMA

TAREK M. EID, MD

Associate Professor of Ophthalmology, Tanta University, Egypt

Glaucoma & Cataract Unit, Magrabi Eye & Ear Center, Jeddah, Saudi Arabia
LASERS IN GLAUCOMA

- LASER: The magic word for the patients:
  - For the REFRACTIVE SURGEON
  - For the CATARACT SURGEON
  - For the PLASTIC SURGEON
  - For the RETINA SURGEON
  - For the GLAUCOMA SURGEON: ???
LASERS IN GLAUCOMA

- POAG, OH, PG, XFG
  - Argon or Selective laser trabeculoplasty
- PACG, PACS, Acute PACG
  - PI, Laser iridoplasty
- 2ry pupillary block NVG, Uveitic
  - Multiple laser iridotomies
- Refractory glaucomas
  - Trans-scleral CPC, Endoscopic CPC
- Malignant glaucoma
  - YAG capsulotomy-hyaloidotomy
- Postop. pressure spikes
  - Laser suture lysis, Goniopuncture, blocked sclerostomy, blocked tubes

Tarek Eid, SLT for glaucoma management, MEACO 2009
Except for ALT & SLT, all other lasers are substitutes for other surgical interventions.

Preferred to surgery with regard to safety, efficacy, cost, and patient’s acceptance of an office procedure.

- Nd:YAG laser membranectomy is effective in reopening blocked glaucoma tube shunts but is associated with a relatively high rate of subsequent reblockage in the initially successful cases. Four tubes (30.8%) remained patent through follow-up periods.
LASERS IN GLAUCOMA

- ALT & SLT are indicated as a primary or adjunctive therapy for pressure control in early to moderate open-angle glaucoma

- What makes them better &
- What makes them worse

Tarek Eid, SLT for glaucoma management, MEACO 2009
LASER TRABECULOPLASTY

- Availability
- Simplicity of the technique
- Safety & tolerability
- Efficacy: short-term & long-term
- Repeatability
- Cost savings

Tarek Eid, SLT for glaucoma management, MEACO 2009
LASER TRABECULOPLASTY

Availability

**ARGON LASER TRABECULOPLASTY**

Use blue-green argon laser

**SELECTIVE LASER TRABECULOPLASTY**

Use Q-switched, frequency-doubled Nd:YAG laser
LASER TRABECULOPLASTY

- **Simplicity of the technique**
- Large spot size of SLT ►► no need to locate a particular zone in TM
- Pigment level is not critical for SLT
- End point is more obvious with ALT

Tarek Eid, SLT for glaucoma management, MEACO 2009
LASER TRABECULOPLASTY

Safety:
- SLT: safe, noninvasive, non thermal
- Targets melanin cells in TM without visible damage to adjacent tissue
- Produces intracellular microdisruption by ultrashort laser pulses (3 nanosec) without dissemination of created heat to surroundings

Human TM – ALT, 50μm spot

Human TM – SLT, 400μm spot

Tarek Eid, SLT for glaucoma management, MEACO 2009
LASER TRABECULOPLASTY

**TOLERABILITY**

- Both SLT & ALT are tolerated by the patient with minimal or no pain during the procedure.
- Postop. pain, anterior chamber reaction, and energy produced during treatment are much less with SLT than ALT.

  - Martiniez et al. SLT vs ALT, hypotensive efficacy, anterior chamber reaction and postoperative pain. EYE 2004;18:498
LASER TRABECULOPLASTY

**EFFICACY**

- Both SLT & ALT produce equivalent reduction of IOP after their first treatment
- SLT reduces IOP equivalent to prostaglandin monotherapy
  - McIlraith et al. Selective laser trabeculoplasty as initial and adjunctive treatment for open-angle glaucoma. J Glaucoma 2006;15:124
LASER TRABECULOPLASTY

• **EFFICACY** of SLT
  • More effective
    • In eyes receiving 360 than 180 degrees treatment
    • In eyes with high baseline IOP
    • In eyes not receiving previous glaucoma medications
      • Katz et al. SLT/Meds Multicenter Study. AAO 2006
      • Eid et al. SLT effect on nonmedically treated vs medically treated eyes. ESCR 2007, Stockholm

• **Similar efficacy** in both phakic and pseudophakic eyes

Tarek Eid. SLT for glaucoma management, MEACO 2009
LASER TRABECULOPLASTY

**EFFICACY**

**Long-term Success of SLT**

- After 6 months: 69% - 92%
- After 1 year: 52% - 98%
- After 2 years: 58% - 88%
- After 3 years: 52% - 76%

LASER TRABECULOPLASTY

REPEATABILITY

- Repeat ALT after 360-treatment is not preferred
  - Less efficacy
  - Postop intractable pressure rise
  - Increased risk of scarring & loss of outflow

- SLT can be repeated on previously treated areas of TM (no thermal damage of treated areas)

- Repeat SLT as effective as initial SLT
  - Nagar M. SLT-effect of enhancement and repeatability. AAO 2006

- SLT is effective after 360 degrees treatment with ALT
  - Tarek Eid, SLT for glaucoma management, MEACO 2009
LASER TRABECULOPLASTY

<table>
<thead>
<tr>
<th>COST SAVINGS</th>
<th>COST SAVINGS</th>
</tr>
</thead>
</table>

Cumulative 6-year cost difference per patient of SLT vs mono-, bi-, tri-drug therapy (Canadian $)

<table>
<thead>
<tr>
<th>SLT repeated 2 yrs vs</th>
<th>2 years</th>
<th>4 years</th>
<th>6 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mono-drug</td>
<td>68</td>
<td>137</td>
<td>206</td>
</tr>
<tr>
<td>Bi-drug</td>
<td>556</td>
<td>1112</td>
<td>1668</td>
</tr>
<tr>
<td>Tri-drug</td>
<td>997</td>
<td>1995</td>
<td>2992</td>
</tr>
</tbody>
</table>

SLT as primary therapy offers a modest potential cost savings over medicinal therapy in the management of OAG – However:

- SLT efficacy is equivalent to monotherapy & not bi-, or tri-drug therapy
- Economics should not drive the treatment paradigm, but it certainly needs to be considered


Tarek Eid, SLT for glaucoma management, MEACO 2009
SLT overcomes many of the adverse effects of medicinal therapy

- Local & systemic side effects to the drops & preservatives
- Continuous use of drops affects quality of life and psychological competence of the patients
- Most glaucoma medications are not targeting the tissue of concern (TM)
- Chronic therapy can compromise or interference with the success of future glaucoma surgery
- Non availability or difficulty to access the medicine in patients in remote areas
- Cost of treatment to the patient & community over the long term
Compliance and rule of laser treatment

- Nearly 45% of patients using electronic monitoring device who were taking one medication and knew they were being monitored and were provided free medication used their drops less than 75% of the time

- Noncompliance is likely to have an important role in the progression to blindness from glaucoma. In this context, laser trabeculoplasty is an attractive option for initial treatment of open-angle glaucoma as compliant is not relevant.
  - EGST Terminology & Guidelines for Glaucoma. 3rd edition, 2008: 144

Tarek Eid, SLT for glaucoma management, MEACO 2009
SELECTIVE LASER TRABECULOPLASTY

shortcomings

- Only glaucoma patients with open angles
- Effect not long lasting with degrading success over time
- Lower efficacy in patients on maximal treatment or on prostaglandins
- Conflicting reports on efficacy in pigmented angles (pigmentary & pseudoexfoliative glaucoma)
- Temporary paradoxical pressure rise after SLT in heavily pigmented eyes
- Treatment cost for non insured patients may not be accepted for asymptomatic disease in its early stages

Tarek Eid, SLT for glaucoma management, MEACO 2009
SELECTIVE LASER TRABECULOPLASTY

- Unrealistic expectations from SLT

MDFD Comments
This lady visited ophthalmology clinic from in patient complaining of severe headache, lac, photophobia and nausea with history of left keratoplasty done at KKESH in Riyadh since 2 weeks and old glaucoma operation. Examination reveals: V/A H.m. no P.L

Anterior Segment examination: Right opaque C graft
- Left keratoplasty with opaque graft
- Ciliary injection with watering
- Stoney hard tension digitally

Posterior Segment Exam: Not seen due to opaque corneas
Diagnosis: Right ab glaucoma with opaque graft
- Left acute attack of glaucoma on top of chronic simple glaucoma with left keratoplasty and opaque graft.

This patient advised for Laser trabecuoplasty. Referred to Ophthalmology Consultation 2nd opinion at Al Maghrabi Hospital, Madhina Al Munawara. Please provide us plan of management of further action.

Referred From: Erfan & Saeedi  Specialty: General Practice
Referred to Case No.: 2365551  Type: Outpatient  Validity: 2 Month(s)  No. of Visits: 00000001

Tarek Eid, SLT for glaucoma management, MEACO 2009
SELECTIVE LASER TRABECULOPLASTY

SLT as a primary treatment for newly diagnosed POAG

- SLT/MED Multicenter study (AAO 2006)
- As effective as medicinal treatment
- Both treatment modalities reached target IOP in most of the patients
- Provide the patient with some few years without glaucoma medications

Tarek Eid, SLT for glaucoma management, MEACO 2009
SELECTIVE LASER TRABECULOPLASTY

- SLT as an adjunctive therapy for mild to moderate POAG
  - An alternative to adding extra drops
  - As adjunctive to current medications to reach target pressure
  - To replace one drop discontinued because of adverse effects
  - As an adjunctive to patients not controlled on maximum therapy before shift to surgery

Tarek Eid, SLT for glaucoma management, MEACO 2009
ALWAYS REMEMBER TO SAVE THE FLOWER

Tarek Eid, SLT for glaucoma management, MEACO 2009